Roche says Gazyva does not meet primary endpoint in phase III testing

ZURICH, July 18 (Reuters) - Roche's Gazyva did not

significantly reduce the risk of disease worsening or death

compared to an alternative treatment for people with previously

untreated diffuse large B-cell lymphoma in a phase III GOYA

test, the company said on Monday.

Read more